KYG 0395

Drug Profile

KYG 0395

Alternative Names: KYG0395

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Jiangsu Kanion Pharmaceutical
  • Class Analgesics; Herbal medicines; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Dysmenorrhoea

Most Recent Events

  • 12 May 2017 No recent reports on development identified - Phase-II for Dysmenorrhoea in USA (PO)
  • 01 Jul 2015 Jiangsu Kanion Pharmaceutical completes a phase II trial in Dysmenorrhoea in USA (NCT01588236)
  • 01 May 2012 Phase-II clinical trials in Dysmenorrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top